Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

BACKGROUND: Metastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased the cos...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Ungari, Andrea Queiróz, Pereira, Leonardo Régis Leira, Nunes, Altacílio Aparecido, Peria, Fernanda Maris
Format: Artigo
Language:Inglês
Published: BioMed Central 2017
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5645838/
https://ncbi.nlm.nih.gov/pubmed/29041915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3679-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items